Health
Commented by André Will-Laudien on October 27th, 2020 | 10:17 CET
Pfizer, GlaxoSmithKline, EXMceuticals - Research in competition
By the end of 2020, the drug market is expected to more than double to USD 1.3 trillion, with the E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - accounting for about one-fifth of global drug sales. Also, the incidence of chronic diseases in developing countries will increasingly resemble that in industrialized countries. The evidence is abundant that the pharmaceutical industry business model is both economically unsustainable and operationally lethargic to produce the types of innovative treatments demanded by global markets. The industry must fundamentally change the way it operates to take full advantage of future growth opportunities. PwC's management consultants expect the industry to shift its focus from treatment to prevention. The traditional blockbuster sales model will disappear, and sophisticated direct sales channels will diminish the role of wholesalers. Let's take a closer look!
Read
Commented by Mario Hose on September 29th, 2020 | 10:51 CEST
BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results
Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.
Read
Commented by Mario Hose on July 29th, 2020 | 07:29 CEST
BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit
The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.
Read
Commented by Mario Hose on June 18th, 2020 | 08:40 CEST
BioNTech, Evotec, EXMceuticals - which stocks have the potential to double?
Experienced investors assume that the DAX, Germany's leading index, will still reach new highs in 2020. One of the best-known supporters of this scenario is the asset manager Dr. Jens Ehrhardt. Rising markets are supported by the measures taken by central banks and politicians - it is de facto the consequence of the increase in the money supply. This expected development will be of particular interest to those investors who have so far been on the sidelines and have to position themselves or reallocate.
Read
Commented by Mario Hose on June 16th, 2020 | 06:30 CEST
Gilead, Teva, XPhyto - Global marketing potential
The best business models solve problems and are scalable. In this context, the healthcare sector is particularly interesting. The world's population has recently reached 7.8 billion people and for this reason solutions can meet a large potential market with users. Cross-border solutions are needed not only for pandemics, but also for diseases that are not mentioned in the mass media but are nevertheless of great importance. A successful market launch is of equal interest to those affected and investors.
Read
Commented by Mario Hose on June 8th, 2020 | 11:30 CEST
Aurora, Bayer, XPhyto - scalable growth markets with potential
Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.
Read
Commented by Mario Hose on June 2nd, 2020 | 05:58 CEST
Memphasys, Moderna, Paion - Investments in solutions with potential
Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.
Read
Commented by Mario Hose on May 26th, 2020 | 07:43 CEST
BioNTech, Evotec, XPhyto - will the next rally start?
Germany's leading index DAX closed the previous day at 11,391 points, its highest level since March 2020. At the beginning of the week the index of the 30 largest German companies gained 317 points compared to Friday, representing a gain of 2.87%. In the USA Wall Street remained closed on Monday due to the Memorial Day. As is well known, the stock market is where the future is traded and for this reason investors are already investing in the prospects of companies in the period following the Corona Pandemic. A rally has begun.
Read
Commented by Mario Hose on May 14th, 2020 | 13:11 CEST
BioNTech, EXMceuticals, Shop Apotheke Europe, Symrise - Shares gaining momentum
The easing of measures to contain the Corona Pandemic will be further extended and, in parallel, companies and their employees will be able to increase personal communications again. However, the curfew phase was also used for strategic decisions and developments, as investors can see from announcements in recent weeks. The situation represents a crisis for many people, but it is also an opportunity for change and a new beginning. Market participants have learned in recent months that dependence on China leads to many bottlenecks and global diversification is therefore necessary. Anyone who wants to be part of it must have the right shares in their portfolio.
Read
Commented by Mario Hose on April 20th, 2020 | 09:43 CEST
Bayer, EXMceuticals, Symrise - investing in the healthcare growth market
The Corona Pandemic brings with it many changes. The influences in the supply chain are affecting the economy to the point of stagnation. The lack of contact for people creates challenges in coping with everyday life. The term 'home office' is used in an inflationary way - and often misused, because the difference between 'home office' and 'working from home' is the noise and stress level around it. On top of this, there are also supply bottlenecks for hygiene products, basic foodstuffs and protective equipment. According to a recent statement by the Federal Minister of Economics, Peter Altmaier (CDU), Germany will need 12 billion masks per year to protect the population. But the well-being of the people also depends on other factors.
Read